Abstract
Alzheimers disease is the most common dementia disorder characterised by a progressive loss of cognitive function. The major neuropathological hallmark for the disease is the presence of beta amyoloid (Aβ) in the brain. The research to date indicates there are multiple factors that can trigger the development of Alzheimers disease. Therefore there are at present several tentative treatment strategies being tested experimentally and clinically. Symptomatic treatment with cholinesterase inhibitors is typically used currently for treatment of Alzheimers disease. New treatment strategies having neuroprotective effects aim to influence the course of the disease and preventing or reducing Aβ accumulation in the brain. This review covers recent findings regarding the experimental and clinical experience with Alzheimers treatments utilizing growth factors, anti-inflammatory drugs, anti-oxidantia, estrogens, cholinergic agonists and anti-amyloid substances.
Current Medicinal Chemistry - Central Nervous System Agents
Title: Neuroprotective Mechanisms as Treatment Strategy in Alzheimers disease
Volume: 1 Issue: 3
Author(s): Agneta Nordberg
Affiliation:
Abstract: Alzheimers disease is the most common dementia disorder characterised by a progressive loss of cognitive function. The major neuropathological hallmark for the disease is the presence of beta amyoloid (Aβ) in the brain. The research to date indicates there are multiple factors that can trigger the development of Alzheimers disease. Therefore there are at present several tentative treatment strategies being tested experimentally and clinically. Symptomatic treatment with cholinesterase inhibitors is typically used currently for treatment of Alzheimers disease. New treatment strategies having neuroprotective effects aim to influence the course of the disease and preventing or reducing Aβ accumulation in the brain. This review covers recent findings regarding the experimental and clinical experience with Alzheimers treatments utilizing growth factors, anti-inflammatory drugs, anti-oxidantia, estrogens, cholinergic agonists and anti-amyloid substances.
Export Options
About this article
Cite this article as:
Nordberg Agneta, Neuroprotective Mechanisms as Treatment Strategy in Alzheimers disease, Current Medicinal Chemistry - Central Nervous System Agents 2001; 1 (3) . https://dx.doi.org/10.2174/1568015013358464
DOI https://dx.doi.org/10.2174/1568015013358464 |
Print ISSN 1568-0150 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6158 |
Related Articles
-
<i>In-silico</i> Prediction of the Beta-carboline Alkaloids Harmine and Harmaline as Potent Drug Candidates for the Treatment of Parkinson’s disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Peripheral Benzodiazepine Receptor (PBR) New Insight in Cell Proliferation and Cell Differentiation Review
Current Clinical Pharmacology Sleep-Related Disorders, Diabetes and Obesity: Understanding the Facts
Current Respiratory Medicine Reviews Mechanisms of Mononuclear Phagocyte Recruitment in Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Heart Failure and Cognitive Impairment: Clinical Relevance and Therapeutic Considerations
Current Cardiology Reviews Foreword
Neuroscience and Biomedical Engineering (Discontinued) The Genetics of Frontotemporal Dementia and Related Disorders
Current Genomics The Detection of Adverse Events in Randomized Clinical Trials: Can we Really Say New Medicines are Safe?
Current Drug Safety Recent Studies on Design and Development of Drugs Against Alzheimer’s Disease (AD) Based on Inhibition of BACE-1 and Other AD-causative Agents
Current Topics in Medicinal Chemistry Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Treatment of Large Vessel Vasculitis
Current Immunology Reviews (Discontinued) Lifestyle and Genetic Contributions to Cognitive Decline and Hippocampal Structure and Function in Healthy Aging
Current Alzheimer Research Sodium-glucose Cotransporter 2 Inhibitors and Ischemic Stroke
Cardiovascular & Hematological Disorders-Drug Targets Genistein: A Phytoestrogen with Multifaceted Therapeutic Properties
Mini-Reviews in Medicinal Chemistry Neurotrophic Factors in Parkinson’s Disease: What Have we Learned from Pre-Clinical and Clinical Studies?
Current Medicinal Chemistry Nanoparticle-Encapsulated Bryostatin-1 Activates α-Secretase and PKC Isoforms In vitro and Facilitates Acquisition and Retention of Spatial Learning in an Alzheimer's Disease Mouse Model
Current Alzheimer Research Electroporation: An Avenue for Transdermal Drug Delivery
Current Drug Delivery Conference Report: 14th International Congress on Amino Acids, Peptides and Proteins, Vienna, Austria, August 3-7, 2015
CNS & Neurological Disorders - Drug Targets Sugars that Glow in the Dark: Fluorescent Tagged Glucose Bioprobes and their Facilitation of the Drug Discovery Process
Current Medicinal Chemistry Cholinergic Activity and Amyloid Precursor Protein Processing in Aging and Alzheimers Disease
Current Drug Targets - CNS & Neurological Disorders